$33.56
4.48% day before yesterday
Nasdaq, Oct 03, 10:00 pm CET
ISIN
US3723032062
Symbol
GMAB

Genmab - ADR Stock price

$33.56
+6.48 23.93% 1M
+14.32 74.43% 6M
+12.69 60.81% YTD
+10.16 43.42% 1Y
-0.24 0.71% 3Y
-4.41 11.61% 5Y
+24.03 252.23% 10Y
+29.79 789.71% 20Y
Nasdaq, Closing price Fri, Oct 03 2025
+1.44 4.48%
ISIN
US3723032062
Symbol
GMAB
Industry

Key metrics

Basic
Market capitalization
$19.6b
Enterprise Value
$19.1b
Net debt
positive
Cash
$507.2m
Shares outstanding
63.3m
Valuation (TTM | estimate)
P/E
12.0 | 12.8
P/S
38.6 | 33.5
EV/Sales
37.6 | 32.7
EV/FCF
108.1
P/B
23.5
Financial Health
Equity Ratio
80.1%
Return on Equity
22.3%
ROCE
17.9%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$508.1m | $585.0m
EBITDA
$173.9m | $217.3m
EBIT
$164.0m | $195.4m
Net Income
$178.3m | $166.2m
Free Cash Flow
$176.9m
Growth (TTM | estimate)
Revenue
25.3% | 19.2%
EBITDA
32.4% | 28.9%
EBIT
26.9% | 21.1%
Net Income
43.5% | -7.1%
Free Cash Flow
44.2%
Margin (TTM | estimate)
Gross
95.1%
EBITDA
34.2% | 37.1%
EBIT
32.3%
Net
35.1% | 28.4%
Free Cash Flow
34.8%
More
EPS
$2.8
FCF per Share
$2.8
Short interest
0.6%
Employees
3k
Rev per Employee
$180.0k
Show more

Is Genmab - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,001 stocks worldwide.

Genmab - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a Genmab - ADR forecast:

18x Buy
69%
7x Hold
27%
1x Sell
4%

Analyst Opinions

26 Analysts have issued a Genmab - ADR forecast:

Buy
69%
Hold
27%
Sell
4%

Financial data from Genmab - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
508 508
25% 25%
100%
- Direct Costs 25 25
151% 151%
5%
483 483
22% 22%
95%
- Selling and Administrative Expenses 88 88
12% 12%
17%
- Research and Development Expense 226 226
21% 21%
44%
174 174
32% 32%
34%
- Depreciation and Amortization 9.89 9.89
385% 385%
2%
EBIT (Operating Income) EBIT 164 164
27% 27%
32%
Net Profit 178 178
44% 44%
35%

In millions USD.

Don't miss a Thing! We will send you all news about Genmab - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Genmab - ADR Stock News

Positive
The Motley Fool
2 days ago
Before the market open on the last trading day of the week, two analysts tracking Genmab (GMAB 4.48%) stock felt compelled to raise their price targets on the biotech. This double-barreled blast of bullishness pushed the company's shares more than 4% higher that trading session, easily beating the essentially stagnant S&P 500 (^GSPC 0.01%).
Neutral
Business Wire
5 days ago
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Merus N.V. (NasdaqGM: MRUS) to Genmab A/S (NasdaqGS: GMAB). Under the terms of the proposed transaction, shareholders of Merus will receive $97.00 in cash for each share of Merus that they own. KSF is s...
Positive
The Motley Fool
5 days ago
One day after announcing a sizable acquisition, Denmark-based biotech Genmab (GMAB 4.67%) was doing well on the stock exchange Tuesday. A pair of analysts weighed in with bullish new takes on the company, helping push it to a nearly 5% price gain in late-session trading.
More Genmab - ADR News

Company Profile

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel in 1999 and is headquartered in Copenhagen, Denmark.

Head office Denmark
CEO Jan Winkel
Employees 2,682
Founded 1998
Website www.genmab.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today